Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). [electronic resource]
Producer: 20140829Description: 951-5 p. digitalISSN:- 1468-2079
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Exudates and Transudates
- Female
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Prospective Studies
- Ranibizumab
- Receptors, Vascular Endothelial Growth Factor -- adverse effects
- Recombinant Fusion Proteins -- adverse effects
- Single-Blind Method
- Subretinal Fluid
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- drug effects
- Wet Macular Degeneration -- diagnosis
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.